Efficacy of risperidone in treating the hyperactive symptoms of delirium.
Forty-one delirious patients who received risperidone treatment and 36 who received haloperidol treatment were retrospectively analysed. Ten-point visual analog scales (scored 0 for none to 10 for extremely severe) for hyperactive and hypoactive syndromes of delirium were used for efficacy evaluation. Psychiatrists scrutinized the medical records and determined the global severity of the syndrome for each patient. The results showed that risperidone and haloperidone were both effective for treating hyperactive symptoms of delirium. The liaison psychiatrists tended to recommend haloperidol for patients with severely hyperactive symptoms and risperidone for older patients and patients with moderate hyperactive symptoms. The patients on risperidone needed much less anticholinergic agent. The maximal daily dose of risperidone was in the range 0.5-4.0 mg, with a mean of 1.17+/-0.76 mg, which was much lower than that for schizophrenia. The present study showed that risperidone appears to be effective and safe for the treatment of delirium.
Liu
Chia-Yih
CY
Department of Psychiatry, Chang Gung Memorial Hospital, Taoyuan, Taiwan. liucy752@cgmh.org.tw
Juang
Yeong-Yu
YY
Liang
Hsin-Yi
HY
Lin
Ni-Chi
NC
Yeh
Eng-Kun
EK
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003693:Delirium / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011595:Psychomotor Agitation / Q000188:drug therapy*; D012189:Retrospective Studies; D018967:Risperidone / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D006220:Haloperidol; D018967:Risperidone